title: Advances in the treatment of newly diagnosed glioblastoma.
abstract: Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients.
authors.affiliation: Department of Neurology and John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Building 19, Bethesda, MD, 20889, USA. brett.j.theeler.mil@mail.mil.
authors.forename: Brett J
authors.initials: BJ
authors.lastname: Theeler
authors.affiliation: National Institutes of Health, 9030 Old Georgetown Road, Bethesda, MD, 20892, USA. mark.gilbert@nih.gov.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Gilbert
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis